PODD - Insulet Corporation

NasdaqGS - NasdaqGS Delayed Price. Currency in USD

Insulet Corporation

600 Technology Park Drive
Suite 200
Billerica, MA 01821
United States

IndustryMedical Instruments & Supplies
Full Time Employees640

Key Executives

Mr. Patrick J. SullivanChairman and Chief Exec. Officer2.03M19.68k65
Ms. Shacey PetrovicPres and Chief Operating Officer1.28MN/A43
Mr. Michael L. LevitzChief Financial Officer, Sr. VP and Treasurer826.41kN/A43
Mr. Bradley A. ThomasExec. VP of HR & Organizational Devel.794.17kN/A59
Mr. Charles AlpucheExec. VP of Global Manufacturing and Operations915.17kN/A57
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Insulet Corporation, a medical device company, develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of the OmniPod, an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device. It also customizes the Omnipod System technology platform for the delivery of subcutaneous drugs across various therapeutic areas. The company sells and markets its Omnipod System through a combination of direct sales representatives and independent distributors. Insulet Corporation was founded in 2000 and is headquartered in Billerica, Massachusetts.

Corporate Governance

Insulet Corporation’s ISS Governance QualityScore as of February 1, 2018 is 6. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 9; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.